SAICoDis – Safety of Argatroban Infusion in Conduction Disturbances. A prospective, open, monocentric safety study to investigate conduction disturbances in patients receiving argatroban therapy.

Trial Profile

SAICoDis – Safety of Argatroban Infusion in Conduction Disturbances. A prospective, open, monocentric safety study to investigate conduction disturbances in patients receiving argatroban therapy.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Argatroban (Primary)
  • Indications Coronary arteriosclerosis
  • Focus Therapeutic Use
  • Acronyms SAICoDis
  • Sponsors Mitsubishi Tanabe Pharma GmbH
  • Most Recent Events

    • 17 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top